Journal article
Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial
M Annala, S Fu, JVW Bacon, J Sipola, N Iqbal, C Ferrario, M Ong, D Wadhwa, SJ Hotte, G Lo, B Tran, LA Wood, JR Gingerich, SA North, CJ Pezaro, JD Ruether, SS Sridhar, HML Kallio, DJ Khalaf, A Wong Show all
Annals of Oncology | ELSEVIER | Published : 2021
Abstract
Background: Treatment of poor prognosis metastatic castration-resistant prostate cancer (mCRPC) includes taxane chemotherapy and androgen receptor pathway inhibitors (ARPI). We sought to determine optimal treatment in this setting. Patients and methods: This multicentre, randomised, open-label, phase II trial recruited patients with ARPI-naive mCRPC and poor prognosis features (presence of liver metastases, progression to mCRPC after <12 months of androgen deprivation therapy, or ≥4 of 6 clinical criteria). Patients were randomly assigned 1 : 1 to receive cabazitaxel plus prednisone (group A) or physician's choice of enzalutamide or abiraterone plus prednisone (group B) at standard doses. Pa..
View full abstractGrants
Awarded by Prostate Cancer Foundation
Funding Acknowledgements
This work was supported by Sanofi, Laval, Quebec, Canada who provided cabazitaxel for use in the study and grant funding for study conduct. Data analysis and correlative studies were funded through research grants from ProstateCancer Canada, Canadian Institutes of Health Research (CIHR) , Movember Foundation, Prostate Cancer Foundation, Terry Fox New Frontiers Program Project Grant [TFF116129] , Jane and Aatos Erkko Foundation, and the Academy of Finland (no grant numbers) . The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report.